XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    52

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,147.33949.73-1.93%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,617.731,261.47-5.28%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,910.39265.44-3.70%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers